However, by hijacking the transcriptional effects of EWSR1::FLI1 on the Werner syndrome helicase WRN, Ewing sarcoma cells can be made hypersensitive to the camptothecin irinotecan, leading to cooperative activity between irinotecan and trabectedin preclinically, and an encouraging 29% response rate in the phase I SARC037 trial in Ewing sarcoma patients treated at the recommended combination phase 2 dose [27,28▪▪]. Here, EWSR1 is linked to Ewing sarcoma.